‘A win-win situation’: Terumo CDMO invests in parenteral drug services
Contract Development and Manufacturing organization (CDMO) Terumo Pharmaceutical Solutions (TPS) announces that it will expand its services. TPS manufactures supplies for injection, primary container, and infusion therapy devices.
Terumo will invest 15 billion Yen, roughly $101m, to expand the CDMO production facilities for pre-filled syringes at its wholly owned subsidiary Terumo Yamaguchi corporation in Yamaguchi City.
With its expansion the CDMO will offer services for parenteral drugs to its global customers engaging in projects ranging from early development stage to large scale commercial production for biotech and small molecule drugs.
The addition to the facility will see a production capacity increase of 3.5 times that of when the plant started operation in 2016.
Aiko Horiuchi, president, CDMO business, pharmaceutical solutions division, explained, that with the expansion TPS can meet customers where they are at and provide the company with fully assembled auto-injectors.
“This is a win-win situation for both patients and healthcare professionals as self-injection systems prove more cost-effective and user-friendly when it comes to administering medicines,” said Horiuchi.
“Our CDMO capabilities will help biopharmaceutical companies to launch effective treatment options for many chronic diseases,” said Noritsugu Fujita, division president, pharmaceutical solutions division.
TPS stated its interest in expanding stems from the expected global increase in CDMO services for injectable drugs the industry expects to see in coming years. Fujita explained, “We expect this business to continue expanding as a growth driver for Terumo Corporation.”
President of TPS Marco Chiago Piat stated that he is excited for the future of Terumo as it is in a “unique position” in its ability to offer an integrated solution for primary container, fill and finish, and device assembly in addition to its traditional offerings.
